Tissue Regenix Group Plc
("Tissue Regenix" or "the Company")
Interim Results and Capital Markets Day
YORK, 22nd October, 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company which uses animal or human tissue to replace damaged or worn out parts of the human body, advises that it will be announcing its unaudited interim results for the six months ended 31 July 2014, on Wednesday 29th October, 2014.
In addition, the Company will be hosting a Capital Markets Event on Wednesday 29th October 2014, with presentations and updates from senior management. Those wishing to attend should register their interest with Newgate Communications.
For Further Information
Tissue Regenix Group Plc: +44 19 0443 5176
Antony Odell
Ian Jefferson
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Newgate Communications: +44 207 6806550
Andrew Adie
Deborah Saw
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.
